Aim The aim of this study was to estimate the prognostic information to be gained from ventricular fibrillation in patients with myocardial infarction.
Introduction
Ventricular fibrillation is experienced in hospital in 10-15% of patients admitted to hospital with acute myocardial infarction. Prompt treatment with defibrillation will restore sinus rhythm in most cases, but the long-term prospects for these patients is uncertain. It is accepted that patients with ventricular fibrillation and congestive heart failure -secondary ventricular fibrillation -constitute a high risk group 1 ' 1 . So-called late ventricular fibrillation -occurring later than 48 h after the infarction -has been associated with a poor prognosis, but in our study of 413 consecutive patients with myocardial infarction complicated by ventricular fibrillation 12 ' the timing of ventricular fibrillation did not appear to influence long-or short-term prognosis.
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Correspondence: Gunnar Jensen, MD, Falkehusene 72, 2620 Albertslund, Denmark. primary ventricular fibrillation, that is ventricular fibrillation not associated with congestive heart failure. In several studies of either non-consecutive retrospective patients' 3 ', or subgroup analysis of selected patients from interventional studies' 4 ', primary ventricular fibrillation (not associated with congestive heart failure) was associated with an elevated in-hospital mortality, while long-term mortality was unaffected by ventricular fibrillation. In the MILIS study' 5 ' primary ventricular fibrillation was found to have no bearing on prognosis. We present a large unselected population of prospectively registered consecutive patients with myocardial infarction from one center.
Patients and methods
The study population comprised 4259 patients, out of a total of 5157 with myocardial infarction admitted to the coronary care unit at Glostrup County Hospital in the period [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] . This department received all cardiac emergencies from the uptake area, which is a suburban region comprising about 250 000 people. There was no age restriction and the same cardiologist, Dr Asger Pedersen, prospectively registered all admissions. Myocardial infarction was denned, according to the World Health Organization criteria, when two of the following were present: (a) typical chest pain and/or pressure, (b) electrocardiographic changes compatible with infarction (c) aspartate aminotransferase or creatine kinase myocardial band elevation. Patients considered to have a high risk of ventricular fibrillation had longer hospitalization (at least 18 days), while patients considered not to be at risk for ventricular fibrillation had short admission times (6-8 days) based on a risk calculation index' 61 . This index has been validated' 61 and ensures registration of all important short-term complications after myocardial infarction.
Thrombolytic treatment was not used and betablockers or platelet inhibition treatment was not routinely used. Coronary angiography and other invasive procedures were restricted to a very few patients with severe unstable angina pectoris refractory to medical treatment.
Ventricular fibrillation was defined as the absence of QRS complexes and T waves on the ECG, and the presence of low-amplitude baseline undulations with variations in both amplitude and periodicity lasting more than 10 s. Ventricular fibrillation was treated promptly (within 1 min) with DC conversion (320 Ws) and a lidocaine bolus (100 mg), followed by an infusion of 180 mg . h~ ' in 24 h. The infusion was then stopped if ventricular ectopic activity ceased. Further antiarrhythmic treatment was administered only in cases of recurrent ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia or ventricular ectopic beats Lown class III-IV). Mexiletine was the first choice antiarrhythmic, and if clinically unsuccesful other antiarrhythmics were tried (quinidine, beta-blockers, amiodarone). The efficacy was tested by continuous electrocardiographic monitoring during the entire hospitalization period and, when feasible, by exercise testing. Congestive heart failure was diagnosed clinically as bilateral pulmonary congestion or oedema by lung stetoscopy or X-ray examination. Cardiogenic shock was diagnosed as systolic blood pressure less than 80 mmHg for more than 30 min, with clinical signs of shock and cardiac failure. The complications in hospital mainly occurred during the first 5 days. Patients who died during the first 5 days of the analyses have been excluded from the study, to ensure that complications related to the clinical terminal phase before death were not included in the analysis. Survival status at follow-up was obtained from the Danish Central Personal Registry after median 7 years and data were complete for 4242 (99-6%) of the patients. Seventeen patients were lost to follow-up.
Statistical methods
Median values and 5 and 95 percentiles were used as descriptive statistics for continuous variables. Univariate comparisons were performed using Wilcoxons rank sum test for continuous variables and chi 2 tests for discrete variables.
Most events occurred during the first few days. To avoid bias from treating time-dependent events as being present from the outset, we only used clinical information from survivors of the first 5 days to generate survival curves and estimate importance of risk factors. Survival curves were calculated using the Kaplan-Meier estimator and compared using the log-rank test. Multivariate analysis of short-term survival (6-30 days after myocardial infarction) was performed using logistic regression and hence the odds ratio was used as a measure for the risk ratio of short-term prognosis. Long-term survival was analysed using proportional hazard models and, accordingly, relative risks were estimated as hazard ratios. The proportionality assumption was checked graphically using log(-log(survival)) plots and the models were found to be feasible when analysing ventricular fibrillation separately in short-term (6-30 days) and long-term (>30 days) models. Some patients were admitted more than once with a myocardial infarction during the study period, but only data from the first admission with myocardial infarction was included in the analyses since subsequent readmissions may be statistically dependent on the first admission.
Results
During the study period, 4259 patients with myocardial infarction were admitted. Ventricular fibrillation was observed in 528 cases (12-4%). We studied the 3433 patients who survived to day 6 after the infarction. Table 1 shows the basic characteristics of the patients, subgrouped by the presence or absence of ventricular fibrillation in hospital. The patients with ventricular fibrillation had larger infarctions, as estimated by maximal creatine kinase myocardial band, and more often signs of congestive heart failure compared to patients without ventricular fibrillation. The survival plot of the patients surviving day 0-5, subgrouped by the presence or absence of ventricular fibrillation is shown in Fig. 1 . The difference is statistically significant (P<00001). Figure 2 illustrates that primary ventricular fibrillation (absence of congestive heart failure) was associated with a better prognosis than secondary ventricular fibrillation (presence of congestive heart failure).
Since mortality was increased predominantly in the period immediately after myocardial infarction ( Figs  1 and 2 ), and to ensure that the assumptions for using the multivariate models were fulfilled, further analyses were divided into short (6-30 day survival) and longterm prognoses (30 day-13 years). Table 2 shows results from multivariate analysis of 30-day survival, given survival until day 6. Prior to initiating the analysis, it was decided to perform a separate analysis of short-and long-term survival, and 30 days was decided as its limit. Ventricular fibrillation has significant independent influence. If patients are subgrouped by the presence of congestive heart failure, primary ventricular fibrillation (without congestive heart failure) was associated with a risk ratio of 6-34 (3-55-11-30, /><00001) not significantly different from secondary ventricular fibrillation (with congestive heart failure) which had a risk ratio of 406 (2-68-614, /><00001). In Table 3 , an attempt is made to analyse when the importance of ventricular fibrillation becomes exhausted during the initial 100 days. This analysis was done a posteriori in order to study for how long ventricular fibrillation adds information to risk of death post-infarction. In Table 3 , we present the result of risk estimation based on the conditional probability of survival until the end of each relevant time interval. As time increases, the importance of ventricular fibrillation decreases. However, the number of events also decrease and therefore the confidence interval widens.
In Fig. 3 long-term prognosis is shown for patients who survived 30 days after myocardial infarction, subgrouped by the presence or absence of congestive heart failure and ventricular fibrillation. Table 4 shows the result of a proportional hazard model of long-term survival. Ventricular fibrillation was not associated with an independent risk of death. When patients were subgrouped by the presence of congestive heart failure, primary ventricular fibrillation (without congestive heart failure) was associated with a risk ratio of 102 (0-76-1-36, P=0-91) and secondary ventricular fibrillation (with congestive heart failure) with a risk ratio of 114 (0-89-1-45, P=0-3).
Discussion
This study has the advantage that all the patients were evaluated and treated under the supervision of the same cardiologist, thus ensuring uniformity in the management of the patients during the entire study period. All the patients were admitted to one centre. Thrombolytic treatment or treatment with aspirin or beta-blockers for secondary prevention is widely used after myocardial infarction in many countries, but was not introduced as routine in our department in the study period.
The study shows that primary as well as secondary ventricular fibrillation are independent risk factors for death during the initial 30 days following myocardial infarction. Ventricular fibrillation could very well be a marker of poor ventricular function or unstable coronary lesions. It is therefore possible that ventricular fibrillation would not be an independent risk factor in a study including detailed information of ventricular func- tion and/or coronary lesions. Ventricular fibrillation is not an independent marker of long-term mortality and it is less likely that further information could change this. An attempt was made to study when the prognostic importance of ventricular fibrillation was exhausted.
The principal results are shown in Table 3 . It is clear that the risk ratio associated with ventricular fibrillation declines with time. However, the number of patients dying during each time interval declines dramatically. The importance of ventricular fibrillation disappears after 60 days, but due to declining mortality this estimate is not very accurate. To our knowledge, no other studies have attempted to estimate exhaustion of ventricular fibrillation as a prognostic factor. The finding that ventricular fibrillation after myocardial infarction is associated with in increased risk of dying in the period immediately after infarction is in accordance with recent studies' 3 ' 47 " 91 . In contrast, Lawrie et al. [l0] found that hospital mortality was unaffected by primary ventricular fibrillation. However, only patients <76 years old were •05
•09
•26 included in their study and they suffered from either ventricular fibrillation or ventricular tachycardia. Only 8-7% of the patients had these arrhythmias, probably because of delayed admittance, the inclusion of younger patients and the use of prophylactic lidocaine therapy.
In the GISSI-I study, patients were treated with aspirin and thrombolysis [4] . The GISSI study population represented approximately 25% of the admitted infarction patients, excluding patients with contraindications to thrombolytic treatment, patients with earlier myocardial infarction and patients admitted later than 12 h after myocardial infarction. In this population, Volpi et a/. [4! found that primary ventricular fibrillation had a significant impact on in-hospital outcome and that primary ventricular fibrillation was important for both thrombolysed and not thrombolysed patients. Our results show that ventricular fibrillation also affects in-hospital prognosis for infarction patients not meeting the inclusion criteria in GISSI-I. In the MILIS study 151 patients were treated with hyaluronidase or propranolol after myocardial infarction. The patients were younger (mean 57 years) and those presenting with cardiogenic shock were excluded. In this study, patients with primary ventricular tachycardia or ventricular fibrillation had the same in-hospital prognosis as patients without these arrhythmias, while patients with secondary ventricular fibrillation had a greater mortality. Norris et a/.
"
1 used i.v. propranolol <4 h after myocardial infarction followed by oral propranolol. This appeared to prevent ventricular fibrillation. Hospital prognosis was the same for treated patients and controls, probably because of the insufficient size of the study population. Other studies of beta-blockers as secondary prevention after myocardial infarction show reduction of mortality and reduced frequency of ventricular fibrillation or sudden cardiac death. This indicates that ventricular fibrillation might be a marker of the elevated risk that is preventable with beta-blockers' 12 " 141 . These studies did not include patients with heart failure contraindicating betablockade and therefore concerns primary ventricular fibrillation. Long-term prognosis among discharged patients was unaffected by the presence or absence of ventricular fibrillation in our study. There seems to be consensus about this result' 1
.
Limitations of the study
It should have been possible in the analysis to take into account more precisely the time of the occurrence of complications under hospitalization, if this information had been available. This would have given prognostic information about the importance of the timing of the ventricular fibrillation or heart failure. The entire study took place before the introduction of thrombolytic therapy. Following its introduction, it is now possible to change the frequency of ventricular fibrillation, and the prognostic importance of ventricular fibrillation could theoretically also change, although this was not the case in GISSI-l' 41 . However, many patients with myocardial infarction are not treated with thrombolytics. Antiarrhythmic treatment, including prophylactic betablocker treatment, was uncontrolled but only a few of the patients were discharged with antiarrhythmics.
Conclusions
Ventricular fibrillation is an independent risk factor for death following myocardial infarction, when risk adjustment can be made for commonly available clinical variables including signs of congestive heart failure. The increased risk associated with ventricular fibrillation is exhausted approximately 2 months after the infarction.
